Bioquark Inc.


Bioquark is dedicated to advancing human health and scientific innovation through health sciences research. The company focuses on fostering collaboration, sharing knowledge, and driving breakthroughs in medical treatments, regenerative medicine, and health wellness. With a mission to create a healthier future for all, Bioquark leverages multidisciplinary research, cutting-edge technologies, and strategic partnerships to address pressing health challenges and improve global health outcomes.

Industries

biotechnology

Nr. of Employees

small (1-50)


Services

Structured research programs exploring regenerative approaches, tissue regulatory state modification, oocyte-derived reprogramming concepts, and discovery of non-human bio-products.

In vivo studies in animal models across multiple indications to assess efficacy endpoints (biomarkers, behavioral measures) and initial safety observations under chronic administration.

Research focused on leveraging oocyte biochemistry to study cellular age resetting, DNA/epigenetic reprogramming, organelle remodeling, and protective mechanisms relevant to tissue repair.

Research initiatives addressing gene editing, microbiome-mental health links, precision nutrition, anti-aging therapies, and skin regeneration relevant to health, wellness, and beauty care.

Activities to create and support collaborations between health initiatives and industry partners, emphasizing data-driven research dissemination and translational progress.

Expertise Areas

  • Regenerative medicine
  • Preclinical in vivo testing and validation
  • Translational clinical development
  • Natural product discovery and interkingdom signaling
  • Show More (6)

Key Technologies

  • Next-generation sequencing
  • Gene editing
  • Bioinformatics
  • Artificial intelligence / Machine learning
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.